
Cigarette giant Philip Morris International has taken control of Vectura, a UK firm that makes medicine and, of all things, devices to treat respiratory illnesses, after a US$1.1 billion bid. PMI, which manufactures Marlboro and Parliament brand cigarettes, said in a statement on Thursday, September 16, that roughly 75% of Vectura’s shareholders had tendered their support for the deal.
“We are very excited about the role Vectura will play in our Beyond Nicotine strategy,” Jacek Olczak, PMI’s CEO, said. The takeover is part of the cigarette group’s long term strategy to become a “broader healthcare and wellness” company with “smoke-free” products.
Nevertheless, the deal has raised hackles at health groups like the British Lung Foundation, Cancer Research UK, and Asthma UK. Reps have questioned whether it is ethical for a tobacco company to own a company that looks to treat the diseases associated with smoking cigarettes, saying it creates “perverse incentives.”
The two organizations sent a letter of protest to the British government, co-signed by 35 medical professionals and charities. Olczak told The Telegraph last month that critics were “not interested in progress” and simply “settling old scores” with his industry.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas